Shares of Quotient QTNT moved higher by 1.2% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 21.62% year over year to ($0.29), which were in line with the estimate of ($0.29).
Revenue of $8,751,000 up by 10.20% from the same period last year, which beat the estimate of $8,300,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Quotient hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Feb 01, 2021
Time: 08:00 AM
ET Webcast URL: https://www.quotientbd.com/media/events-and-presentations
Technicals
52-week high: $10.38
Company's 52-week low was at $2.40
Price action over last quarter: Up 13.52%
Company Description
Quotient Ltd is a commercial-stage diagnostics company. It is involved in the business of provision of tests with an initial focus on blood grouping and serological disease screening. The company develops and commercializes Mosaiq automation platform. Its product portfolio includes Red cell reagents, Antisera, Specialty products, Specialty kits etc. The firm operates in Edinburgh, Scotland, Eysins, Switzerland and Newton, Pennsylvania. It derives the majority of its revenue from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.